Mankind Pharma is one of India's largest prescription-pharmaceutical companies, spanning acute and chronic formulations, consumer healthcare (OTC) products and specialty brands through its BSV division, and it reports into a domestic pharma market that accelerated through the September quarter. The print will speak most to whether gross margin holds above the guided 71% floor as commodity and dollar costs flow through, and whether secondary sales return to outperforming the IPM after trailing it marginally in Q1 FY27.
| Results date | October 26, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 4,031 Cr |
| Previous quarter PAT | Rs. 574 Cr |
| Previous quarter EBITDA margin | 26.3% |
| Net debt (latest quarter) | Rs. 3,377 Cr |
| Market cap | Rs. 93,067.32 Cr |
| CMP | Rs. 2,253.2 |
The board meets on October 26, 2026 to consider and approve the audited financial results for the quarter and half year ended September 30, 2026 (Q2/H1 FY27). The trading window remains shut till October 28, 2026.
The Q2/H1 FY27 earnings call is scheduled for October 26, 2026 at 6:00 PM IST.
The quarter's central test is gross margin: management itself flagged possible compression in Q2 FY27 from rising commodity and dollar prices against a maintained 'upward of 71%' FY27 floor, after Q1's 72.8% was aided by an elevated inventory buffer. The demand backdrop is supportive — IPM value growth ran +12.1% in July, +10.7% in August and +13.5% in September, with the IQVIA-based Q2 aggregate at +14.7% YoY versus +13.9% in Q1 — giving Mankind a fair shot at returning to its guided 'outperform IQVIA' trajectory after Q1 secondary sales of +12.7% trailed IPM's +13.0%. The new-launch contribution gap (2.8% for Mankind vs IPM's 4.1% in Q1) is the swing item, with Semaglutide and the exclusively in-licensed Insulin Degludec (secured August 20) the products to scale. On the balance sheet, net debt/adjusted EBITDA stood at 0.9x at Q1 FY27 against a 0.5x target by FY27, with a Rs. 1,250 Cr NCD repayment due October 2026. The call is also the first reporting period after the October 15 approval to acquire 70% of Belgium-based ACTx for EUR 48Mn, and BSVL's voluntary liquidation remains subject to creditor approval under IBC, 2016.
Performance vs guidance tracking: Where the FY27 guidance stack stood entering the Q2 print:
Gross margin bridge and input costs: The key margin swing factor for the quarter:
Strategic actions: ACTx, BSVL and Insulin Degludec: Corporate actions since the last call that will shape the consolidated numbers:
Consumer Healthcare and secondary sales recovery: Whether the guided inflection shows up in Q2:
Management has guided for a consolidated EBITDA margin of 25.5% to 26.5% for FY27, with the CFO calling it a reliable guidance while caveating geopolitical and market conditions. Q1 FY27 came in at 26.3%.
Semaglutide was launched about a month before the May 2026 call, targeting endocrinologists first with a therapy-focused, KOL-led approach. Managing Director Rajeev Juneja described the delay as a strategic, contrarian decision amid a market with 20+ companies and 35-40 GLP-1 brands and significant price drops.
Yes — the repayment schedule was reconfirmed at the Q1 FY27 call: Rs. 1,250 Cr of NCDs was paid in April 2026, Rs. 1,250 Cr is due October 2026 and Rs. 2,500 Cr the following year. Net debt/adjusted EBITDA stood at 0.9x at Q1 FY27, with a 0.5x target by FY27 and full acquisition-debt repayment by FY28.
On October 15, 2026, the board approved acquiring 70% of Armed Cell Therapeutics B.V. for EUR 48Mn payable in cash instalments, plus up to EUR 45Mn of additional funding into Mankind Pharma (Netherlands) B.V. within an aggregate limit of EUR 50Mn. ACTx develops next-generation armed CAR-T cancer therapies with lead programs in non-Hodgkin lymphoma and small cell lung cancer.
CEO Sheetal Arora has said acute therapy growth would be in line with IPM growth for FY27. Anti-infectives recovered to +3.6% in Q1 FY27 from -1.1% in Q4 FY26, with lost GP penetration from the team rejig being progressively regained.